이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Samsung invests in BrickBio to advance precision biologics

Collected: 2024.03.19

Distributed: 2024.03.20

Source: Go Direct

[Courtesy of BrickBio]

Samsung Life Science Fund, jointly created by Samsung Biologics Co., Samsung Bioepis Co., and Samsung C&T Corp., announced plans to invest in BrickBio Inc., a preclinical-stage biopharmaceutical company focused on developing precision biologics using antibody-drug conjugates (ADCs).

BrickBio has developed technology that utilizes tRNA to bind artificial amino acids to specific locations on proteins.

TRNA, involved in the synthesis of various proteins, allows for the insertion of artificial amino acids to function selectively at desired protein locations. This technology facilitates the modification of antibody structures necessary for combining antibodies and drugs in ADCs.

Based on BrickBio’s technology, Samsung aims to explore business opportunities related to the development and production of therapeutics in various fields such as ADCs and adeno-associated viruses (AAVs).

BrickBio’s platform, which incorporates synthetic amino acids into proteins within living cells, enables the creation of precision biologics. These biologics offer promising applications and potential for treating various diseases effectively.

“BrickBio’s robust expanded genetic code in mammalian cells offer the potential to create molecules and therapies to address unmet needs,” said Cho Ho-sung, executive vice president and head of Early Research and Development of Samsung Bioepis.

So far, Samsung Life Science Fund has invested in Jaguar Gene Therapy, a U.S. gene therapy development company, Senda Biosciences, a U.S. nanoparticle drug delivery developer, and Araris Biotech, a Swiss ADC technology company.

By Pulse

List

Previous: Korean bio, healthcare stocks gain on U.S. Biosecurity Act

Next: Samsung Electronics introduces eco-friendly battery packs